Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study

Cancer Treat Rep. 1976 May;60(5):535-9.

Abstract

Thirty-four patients with recurrent squamous cell carcinoma of the head and neck were randomized to receive the five-drug chemotherapy regimen BACON (bleomycin, adriamycin, CCNU, vincristine [Oncovin], and mechlorethamine [nitrogen mustard]; 14 patients) or the same regimen plus bacillus Calmette-Gu erin (BCG) by scarification (20 patients). The majority of both patient groups had received prior surgery and radiation. The patients treated with BACON plus BCG experienced a significantly longer survival (P = 0.014) than those treated with BACON alone. There were five drug-related deaths, and eight other patients required hospitalization for treatment of drug-related morbidity.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • BCG Vaccine / therapeutic use
  • Bleomycin / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / therapy
  • Doxorubicin / therapeutic use
  • Female
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / immunology
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Lomustine / therapeutic use
  • Male
  • Mechlorethamine / therapeutic use
  • Middle Aged
  • Remission, Spontaneous
  • Retrospective Studies
  • Texas
  • Vincristine / therapeutic use

Substances

  • Antineoplastic Agents
  • BCG Vaccine
  • Bleomycin
  • Mechlorethamine
  • Vincristine
  • Lomustine
  • Doxorubicin